Premium
The Effects of a Combination Nutraceutical Therapy on CVD Risk Biomarkers in a Population of Generally Healthy Dyslipidemic Adults
Author(s) -
Pins Joel J.,
Dodds Ellen,
Stoltz Tom,
Keenan Joseph M
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.5.lb94-b
Subject(s) - medicine , nutraceutical , placebo , overweight , population , lipid profile , clinical trial , diabetes mellitus , blood lipids , obesity , cholesterol , endocrinology , environmental health , pathology , alternative medicine
In recent years combination dietary strategies and drug therapies have grown in popularity to help at‐risk populations attain their NCEP ATP III blood lipid goals. While much less is known about dietary supplements, the same enhanced lipid‐altering effects may exist with combinations of these agents. Therefore, we conducted the first uncontrolled pilot trial (N=5) investigating the combined lipid‐altering effects of fish oils (EPA/DHA 2.5 g/d), pantethine (600 mg/d), and phytosterols (1.5 g/d). Five generally healthy overweight (BMI = 28.5 ± 3.1) dyslipidemic adults (36–67 years) without a history of CVD were enrolled in this 4‐week study. Subjects were free of diabetes at baseline and used no lipid‐altering medications or dietary supplements. Subjects were encouraged to maintain their weight, diet, and other lifestyle habits throughout the study. Body weights were assessed and blood samples and side effect questionnaires were collected at baseline and at day 28 of treatment. Treatment was three capsules b.i.d. with meals (open label). All 5 subjects completed the study. Body weight, diet, and activity levels were unchanged during the treatment period. Treatment was well tolerated with a 98% compliance rate. CVD Risk Factor Results at Baseline and Post‐treatment:The results of this pilot study warrant further investigation in a fully powered placebo‐controlled clinical trial.